# Quantum Computing in Drug Discovery: A Critical Assessment of Algorithmic Feasibility, Resource Requirements, and Practical Utility

## Executive Summary

The pharmaceutical industry's productivity crisis—characterized by development costs exceeding $2.6 billion per drug, 12–15 year timelines, and high clinical attrition rates [14]—is driven in part by the inability of classical computing to exactly solve the electronic Schrödinger equation for pharmacologically relevant molecules [1,2]. Quantum computing has emerged as a candidate technology for addressing this bottleneck [1,3]. However, the field suffers from a disconnect between aspirational claims and quantitative reality. This report provides a critical, technically grounded assessment of quantum computing's current and projected utility in drug discovery. Rather than surveying the field broadly, it focuses on a specific analytical contribution: a comparative resource and accuracy analysis that evaluates where quantum electronic structure methods could meaningfully improve pharmaceutical decision-making relative to state-of-the-art classical approaches. The central finding is that for the foreseeable future, the dominant sources of error in drug discovery computations—conformational sampling, solvation modeling, and protein force field accuracy—dwarf the electronic structure improvements quantum computing could provide for most applications, confining quantum advantage to narrow but important niches involving strong electron correlation, such as metalloenzyme active sites and covalent inhibitor design [2,8].

## Introduction: Defining the Computational Bottleneck Precisely

Drug discovery requires predicting how small molecules interact with biological targets with sufficient accuracy to guide medicinal chemistry decisions [1,4]. In practice, this means computing relative binding free energy differences with errors below approximately 1.0 kcal/mol to reliably rank congeneric compound series [2,3]. The total error in such predictions arises from multiple sources: the electronic structure description of the ligand and active site, the molecular mechanics force field for the protein environment, conformational sampling adequacy, solvation free energy estimation, and entropic contributions [2,10]. Classical methods such as density functional theory (DFT) and coupled cluster theory (CCSD(T)) address only the first of these error sources, and their computational cost scales polynomially to exponentially with system size [1,2].

Quantum computing can in principle represent molecular wavefunctions exactly using a polynomial number of qubits [1,6], but the critical question for drug discovery is not whether quantum computers can solve electronic structure problems more accurately than classical computers in the abstract—they can, given sufficient resources—but whether that accuracy improvement propagates meaningfully through the full computational pipeline to change pharmaceutical outcomes [2]. This report addresses that question through quantitative analysis of resource requirements, accuracy benchmarks, and error budget decomposition.

## Quantum Algorithms: Technical Depth and Resource Analysis

### Variational Quantum Eigensolver: Ansatz Design, Circuit Costs, and Accuracy

The variational quantum eigensolver (VQE) is the most explored near-term quantum algorithm for molecular simulation [1,2,3]. VQE uses a parameterized quantum circuit to prepare a trial wavefunction and a classical optimizer to minimize the energy expectation value [1,2]. However, the algorithm's practical utility depends critically on ansatz choice, which determines circuit depth, parameter count, and accuracy.

The unitary coupled cluster singles and doubles (UCCSD) ansatz provides systematically improvable accuracy but requires circuit depths that scale as O(N⁴) in the number of spin-orbitals, rendering it infeasible for molecules beyond approximately 20 spin-orbitals on current hardware [2,3]. Hardware-efficient ansätze reduce circuit depth but lack chemical motivation, making them highly susceptible to the barren plateau problem—the exponential flattening of the optimization landscape with increasing qubit count, first characterized rigorously by McClean et al. (2018) [2,3]. Adaptive approaches such as ADAPT-VQE, which iteratively grow the ansatz by selecting operators from a pool based on energy gradient magnitudes, offer a compromise by constructing compact, problem-tailored circuits, but they require substantially more quantum measurements per iteration [2,3].

To ground these considerations quantitatively: VQE calculations on current hardware have achieved chemical accuracy (errors below 1.6 kcal/mol or 1 millihartree) only for very small molecules—H₂ (2–4 qubits), LiH (8–12 qubits), and BeH₂ (12–14 qubits) [1,2,3]. By contrast, a typical drug-like molecule with 30–60 heavy atoms requires 200–600 spin-orbitals for a full electronic description [2]. Even with active space selection restricting the quantum calculation to the most chemically important orbitals, pharmaceutically relevant active spaces (such as the iron-porphyrin core of cytochrome P450) demand 40–80 spin-orbitals, translating to 40–80 qubits under Jordan-Wigner encoding before accounting for circuit depth and measurement overhead [2].

### Encoding Schemes and Their Impact on Circuit Complexity

The mapping from fermionic molecular orbitals to qubit representations introduces significant overhead that varies by encoding scheme [1,2]. The Jordan-Wigner transformation maps N spin-orbitals to N qubits but requires O(N) Pauli strings per fermionic operator, resulting in two-qubit gate counts that scale unfavorably for large systems [1,2]. The Bravyi-Kitaev encoding reduces the Pauli weight of operators to O(log N) at the cost of more complex qubit-operator relationships [1,2]. For a system of 50 spin-orbitals, Jordan-Wigner encoding produces Hamiltonian terms with Pauli strings of weight up to 50, whereas Bravyi-Kitaev reduces this to weight approximately 6, significantly decreasing the two-qubit gate count per Hamiltonian term [2]. More recent compact encodings and symmetry-adapted mappings exploit molecular point group symmetry and particle number conservation to reduce qubit requirements by 20–40% for symmetric molecules, though the benefits are system-dependent [2,10].

Hamiltonian decomposition techniques further affect feasibility. Double factorization of the two-electron integrals can reduce the number of terms in the Hamiltonian from O(N⁴) to O(N²) or better, directly decreasing measurement overhead [2,8]. Tensor hypercontraction achieves even greater compression, reducing the Toffoli gate count for fault-tolerant simulations by roughly an order of magnitude compared to naive implementations [2].

### Quantum Phase Estimation: Fault-Tolerant Resource Estimates

Quantum phase estimation (QPE) offers exponential speedup over classical full configuration interaction but requires fault-tolerant hardware [1,2]. Resource estimation studies provide concrete benchmarks for pharmaceutical targets. Reiher et al. (2017) estimated that simulating the FeMo-cofactor of nitrogenase—a system with 54 active-space orbitals and strong multireference character—would require approximately 100 logical qubits and 10¹⁵ T-gates using Trotterized time evolution [2]. Subsequent algorithmic improvements via qubitization reduced this to approximately 4,000 logical qubits and 10¹⁰ Toffoli gates [2]. Blunt et al. estimated that cytochrome P450 active-site simulations would require similar logical qubit counts (2,000–4,000) with millions of T-gates, translating to physical qubit requirements of 1–10 million depending on the error correction code and physical error rates [2]. These estimates, while dramatically improved from early projections, remain well beyond current hardware capabilities of approximately 1,000–1,500 noisy physical qubits [6].

## Critical Error Budget Analysis: Where Does Quantum Accuracy Matter?

The central question for drug discovery is whether quantum-level electronic structure improvements translate into better pharmaceutical decisions. A quantitative error budget analysis reveals that the answer is application-dependent.

### Binding Free Energy Prediction

State-of-the-art classical free energy perturbation methods (e.g., FEP+) achieve root-mean-square errors of approximately 0.9–1.2 kcal/mol for relative binding free energies of congeneric compound series [2,3]. This error decomposes approximately as follows: force field inaccuracies for the protein-ligand complex contribute roughly 0.5–0.8 kcal/mol; conformational sampling limitations contribute 0.3–0.6 kcal/mol; solvation model errors contribute 0.2–0.4 kcal/mol; and the electronic structure approximation for the ligand contributes approximately 0.1–0.3 kcal/mol for typical organic drug molecules without strong correlation effects [2,10]. Since the electronic structure component is already the smallest contributor, improving it to exact accuracy via quantum computing would reduce total RMSE by at most 0.1–0.3 kcal/mol for standard drug-like molecules—a marginal improvement unlikely to change compound rankings in most medicinal chemistry campaigns.

However, for systems involving transition metal coordination (metalloenzyme inhibitors), covalent bond formation (covalent inhibitors), or significant charge-transfer character, the electronic structure contribution to error can increase to 1–3 kcal/mol or more, as DFT and even DLPNO-CCSD(T) struggle with multireference correlation effects [2,10]. In these cases, quantum computing could provide meaningful accuracy improvements. Metalloenzymes such as cytochrome P450s, histone deacetylases (zinc-dependent), and kinases with covalent inhibitor binding represent the strongest near-term use cases for quantum-enhanced electronic structure in drug discovery [2,8].

### Virtual Screening Throughput

Classical docking programs such as Glide SP screen approximately 10⁶–10⁷ compounds per day on modest computational clusters [3,14]. A single VQE energy evaluation on current hardware requires 10³–10⁵ circuit executions (shots) to achieve acceptable statistical precision, with each circuit execution taking microseconds to milliseconds depending on circuit depth, plus classical communication and optimization overhead [2,6]. Even assuming optimistic future hardware with microsecond circuit times and 10⁴ shots per energy evaluation, a quantum-enhanced scoring function evaluating one energy point per compound would process approximately 10³–10⁴ compounds per day—three to four orders of magnitude slower than classical docking [2,6]. This throughput gap makes quantum-enhanced virtual screening impractical for primary screening campaigns. A more viable strategy is to use quantum calculations selectively for rescoring top-ranked hits from classical screens, where the smaller compound set (10²–10³ molecules) makes quantum evaluation feasible [8,13].

## Hybrid Quantum-Classical Frameworks and the Quantum Data Advantage

Given these constraints, the most pragmatic near-term pathway is hybrid frameworks that deploy quantum computing selectively within classical workflows [7,8]. Zhou et al.'s quantum-machine-assisted drug discovery (QMADD) paradigm exemplifies this approach: quantum processors generate high-accuracy electronic structure data for training sets of representative molecules, and classical machine learning models trained on these data perform rapid inference across large compound libraries [8,13]. This "quantum data advantage" strategy circumvents the throughput limitation by amortizing expensive quantum calculations across many predictions [8,13].

The Tierkreis dataflow framework provides the software infrastructure for such hybrid pipelines, enabling seamless composition of quantum circuit execution with classical pre- and post-processing [7]. Quantum kernel methods and quantum neural networks have shown preliminary advantages in learning molecular representations from small training datasets, potentially addressing data scarcity in early-stage discovery [3,4]. The integration of quantum computing with AI-driven platforms, including emerging LLM-based agent frameworks for coordinating discovery workflows [5], further suggests that quantum computing's pharmaceutical impact will be mediated through classical AI systems rather than through direct quantum computation on every molecule of interest.

## Identifying the Highest-Value Applications

Based on the error budget and resource analysis above, quantum computing's near-term pharmaceutical value concentrates in specific niches. First, metalloenzyme active-site characterization, where strong electron correlation defeats classical methods, represents the clearest case for quantum advantage once hardware reaches approximately 50–100 logical qubits [2,8]. Second, covalent inhibitor design, requiring accurate description of bond-forming transition states with multireference character, would benefit from quantum electronic structure calculations integrated into QM/MM workflows [8,10,11]. Third, high-fidelity training data generation for machine learning models of molecular properties, where quantum calculations on small representative sets improve model accuracy across chemical space, offers practical value before fault-tolerant hardware is available [8,13]. Fourth, combinatorial optimization problems in compound library design and synthesis planning, which require fewer qubits and tolerate higher error rates, may deliver value through quantum approximate optimization algorithms (QAOA) or quantum annealing [3,6,14].

Conversely, routine lead optimization of organic drug molecules without strong correlation effects, primary virtual screening campaigns requiring high throughput, and applications where conformational sampling rather than electronic structure accuracy is the bottleneck are unlikely to benefit meaningfully from quantum computing in the foreseeable future [2,10].

## Challenges and Realistic Timeline

The most immediate barriers remain hardware-related: current devices offer approximately 1,000–1,500 noisy physical qubits, whereas pharmaceutically relevant fault-tolerant calculations require 1–10 million physical qubits [2,6]. The QM/MM interface problem—coupling quantum-computed active-site regions with classically described protein environments without degrading quantum accuracy—remains methodologically unsolved [8,11]. Error mitigation techniques including zero-noise extrapolation and probabilistic error cancellation extend NISQ utility but cannot substitute for full error correction [2,3].

Industry engagement continues to deepen, with Roche, Biogen, Merck, and Boehringer Ingelheim maintaining quantum computing research programs [12,14,16]. Realistic projections suggest that quantum data advantage applications (training data generation) may deliver value within 3–5 years, targeted metalloenzyme calculations within 5–10 years contingent on hardware progress, and broad pharmaceutical quantum advantage within 10–15+ years [14,15,16].

## Conclusion

Quantum computing's value in drug discovery is real but narrower than often claimed. The quantitative analysis presented here demonstrates that for most standard drug discovery tasks, the electronic structure component of computational error is small relative to sampling, solvation, and force field contributions, limiting the impact of quantum accuracy improvements. The strongest cases for quantum advantage involve systems with strong electron correlation—metalloenzymes, covalent inhibitors, and charge-transfer complexes—where classical electronic structure methods fail qualitatively rather than merely quantitatively [2,8]. The most productive near-term strategy combines selective quantum calculations for these challenging systems with classical machine learning for broad chemical space exploration [7,8,13]. The field would benefit from moving beyond aspirational narratives toward rigorous, application-specific assessments of where quantum resources are worth deploying—a shift from asking "Can quantum computers help drug discovery?" to "For which specific pharmaceutical problems do quantum calculations change the answer?" [2,3,14].

## References

[1] Yudong Cao, Jonathan Romero, Alán Aspuru-Guzik (2018). "Potential of quantum computing for drug discovery". *IBM Journal of Research and Development*. https://doi.org/10.1147/jrd.2018.2888987

[2] Nick S. Blunt, Joan Camps, Ophelia Crawford et al. (2022). "Perspective on the Current State-of-the-Art of Quantum Computing for Drug Discovery Applications". *Journal of Chemical Theory and Computation*. https://doi.org/10.1021/acs.jctc.2c00574

[3] Gautam Kumar, Sahil Yadav, Aniruddha Mukherjee et al. (2024). "Recent Advances in Quantum Computing for Drug Discovery and Development". *IEEE Access*. https://doi.org/10.1109/access.2024.3376408

[4] Ruby Srivastava (2023). "Quantum computing in drug discovery". *Information System and Smart City*. https://doi.org/10.59400/issc.v3i1.294

[5] Namkyeong Lee, Edward De Brouwer, Ehsan Hajiramezanali et al. (2025). "RAG-Enhanced Collaborative LLM Agents for Drug Discovery". *arXiv*. http://arxiv.org/abs/2502.17506v3

[6] Sukhpal Singh Gill, Oktay Cetinkaya, Stefano Marrone et al. (2024). "Quantum Computing: Vision and Challenges". *arXiv*. http://arxiv.org/abs/2403.02240v5

[7] Seyon Sivarajah, Lukas Heidemann, Alan Lawrence et al. (2022). "Tierkreis: A Dataflow Framework for Hybrid Quantum-Classical Computing". *arXiv*. http://arxiv.org/abs/2211.02350v1

[8] Yidong Zhou, Jintai Chen, Jinglei Cheng et al. (2024). "Quantum-machine-assisted Drug Discovery". *arXiv*. http://arxiv.org/abs/2408.13479v5

[10] Virendra Gomase, Arjun P. Ghatule, Rupali Sharma et al. (2025). "Quantum Computing in Drug Discovery Techniques, Challenges, and Emerging Opportunities". *Current Drug Discovery Technologies*. https://doi.org/10.2174/0115701638371707250729040426

[11] Dr. Pushpalata Patil, Ravindra D Patil, Dr. Sandeep Kulkarni (2025). "Quantum Computing in Drug Discovery: A Review of Foundations and Emerging Applications". *International Journal of Advanced Pharmaceutical Sciences and Research*. https://doi.org/10.54105/ijapsr.e4078.05040625

[12] R. Mullin (2020). "Let's talk about quantum computing in drug discovery". *Semantic Scholar*. https://doi.org/10.1021/CEN-09835-FEATURE2

[13] "Quantum-machine-assisted drug discovery". *npj Drug Discovery*. https://www.nature.com/articles/s44386-025-00033-2

[14] "Quantum computing in life sciences and drug discovery". *McKinsey & Company*. https://www.mckinsey.com/industries/life-sciences/our-insights/the-quantum-revolution-in-pharma-faster-smarter-and-more-precise

[15] "How quantum computing is changing molecular drug development". *World Economic Forum*. https://www.weforum.org/stories/2025/01/quantum-computing-drug-development/

[16] "How quantum computing is revolutionising drug development". *Drug Discovery World*. https://www.ddw-online.com/how-quantum-computing-is-revolutionising-drug-development-34423-202504/